Ann Dermatol.  2014 Aug;26(4):532-533. 10.5021/ad.2014.26.4.532.

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate

• Song HS
• Kang HY

• KMID: 2265603
• DOI: http://doi.org/10.5021/ad.2014.26.4.532

Abstract

No abstract available.

MeSH Terms

Hyperpigmentation*
Nose*
Palate*
Imatinib Mesylate

Figure

• 

  Fig. 1 Ill-defined slate grey-colored pigmentation on nose (A) and palate (B).

• 

  Fig. 2 (A) Increased epidermal pigmentation and dermal melanophages in the lesional skin (L) compared with perilesional normal skin (N) (Fontana-Masson stainining, ×200). (B) There were no melanocytes in the dermis (gp100, ×200).

Reference

1. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003; 48:201–206.

2. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003; 98:2483–2487.

3. Mcpherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009; 23:82–83.

4. Resende RG, Teixeira RG, Vasconcelos Fde O, Silva ME, Abreu MH, Gomez RS. Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Craniomaxillofac Surg. 2012; 40:e140–e143.

5. Cario-André M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A. Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol. 2006; 155:493–494.